Bad Homburg vor der Höhe

Option Care Health Appoints Dr. Seema Kumbhat to the Position of Chief Medical Officer

Wednesday, July 28, 2021 - 2:00pm

BANNOCKBURN, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the Company or Option Care Health)(Nasdaq: OPCH), the nations largest independent provider of home and alternate site infusion services, announced today that Dr. Seema Kumbhat has joined the Company as Chief Medical Officer.

Key Points: 
  • BANNOCKBURN, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the Company or Option Care Health)(Nasdaq: OPCH), the nations largest independent provider of home and alternate site infusion services, announced today that Dr. Seema Kumbhat has joined the Company as Chief Medical Officer.
  • Prior to joining Option Care Health, Dr. Kumbhat served as Senior Vice President and Regional Medical Officer for Fresenius Kabi.
  • As a physician, she brings a wealth of knowledge to the Option Care Health team, and Im confident she will make a positive impact in continuing efforts to elevate patient care, John Rademacher, Chief Executive Officer, commented.
  • Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.

Fresenius Medical Care North America Announces New President for Renal Therapies Group

Thursday, July 22, 2021 - 6:00pm

WALTHAM, Mass., July 22, 2021 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company's Renal Therapies Group.

Key Points: 
  • WALTHAM, Mass., July 22, 2021 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company's Renal Therapies Group.
  • Turk succeeds Mark Costanzo, who recently retired as President of FMCNA's Renal Therapies Group.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.

UPS Healthcare Announces Agreement With Fresenius Medical Care, Expanding Service In The UK

Thursday, July 22, 2021 - 6:00am

Through this agreement, Polar Speed will assume operation of Fresenius Medical Care's facility in Huthwaite, Nottinghamshire, UK, adding to Polar Speed's GDP-compliant depot network.

Key Points: 
  • Through this agreement, Polar Speed will assume operation of Fresenius Medical Care's facility in Huthwaite, Nottinghamshire, UK, adding to Polar Speed's GDP-compliant depot network.
  • Wes Wheeler, President of UPS Healthcare, said, "UPS Healthcare is delighted to work with Fresenius Medical Care as a supply chain partner in the UK.
  • "One of the ongoing strategic priorities for Fresenius Medical Care is to constantly review and improve our operations," said Tim Wheeldon, Managing Director and Head of Fresenius Medical Care UK and Ireland.
  • Fresenius Medical Care UK has been caring for NHS kidney patients in the UK for over 20 years.

Ambulnz Launches Service in Illinois

Wednesday, July 14, 2021 - 12:20pm

With this latest expansion, Ambulnz will be able to serve 9 Fresenius Kidney Care centers in Illinois, with plans to expand coverage to an additional 50 Chicago-area clinics in the coming months.

Key Points: 
  • With this latest expansion, Ambulnz will be able to serve 9 Fresenius Kidney Care centers in Illinois, with plans to expand coverage to an additional 50 Chicago-area clinics in the coming months.
  • Ambulnz will assist people getting to and from scheduled dialysis appointments.
  • Dialysis patients in Illinois using Ambulnz services can now get dedicated and reliable transportation to and from their kidney dialysis appointments.
  • Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care.

Xenios AG receives approval in China for ECMO devices

Tuesday, July 13, 2021 - 8:51am

In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China.

Key Points: 
  • In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China.
  • As a result, a complete Xenios system is now permitted for ECMO therapy in China.
  • This Xenios ECMO complete system is certified in China for nine days application period.
  • The expedited approval was a joint effort by Xenios and Fresenius Medical Care China Team.

Fresenius Medical Care Supports Education for Healthcare Professionals in Korea With the Opening of Its First Training Center

Monday, June 28, 2021 - 2:45am

Certified trainers from Fresenius Medical Care, together with regional clinical education experts from across Asia Pacific, will provide best practice training for healthcare professionals within the renal care field.

Key Points: 
  • Certified trainers from Fresenius Medical Care, together with regional clinical education experts from across Asia Pacific, will provide best practice training for healthcare professionals within the renal care field.
  • With the opening of the Training Center, Fresenius Medical Care Korea pledges its ongoing support of healthcare professional education.
  • The Fresenius Medical Care Training Center also offers educational opportunities catering to individual healthcare professionals specializing in particular treatment modalities such as PD, HD, and CRRT.
  • The Fresenius Medical Care Training Center will provide healthcare professionals with high-standard, systematic training, helping them to advance their knowledge and skills in renal and critical care.

Vifor Pharma to revise DIAMOND study, readout expected in H2 2021

Thursday, June 24, 2021 - 6:00am

More than 1,000 patients with heart failure and with hyperkalemia or history of hyperkalemia have already been enrolled in DIAMOND.

Key Points: 
  • More than 1,000 patients with heart failure and with hyperkalemia or history of hyperkalemia have already been enrolled in DIAMOND.
  • Following the change of endpoints, study read-out and remaining data collection is expected to be completed in 2021.
  • Vifor Pharma will host a conference call today, 24 June 2021 at 10:30 am (CET).
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

Fresenius Kabi Receives Premier Supplier Legacy Award

Monday, June 21, 2021 - 2:00pm

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received a 2021 Supplier Legacy Award from Premier Inc. ( www.premierinc.com ), a leading health care improvement company.

Key Points: 
  • Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received a 2021 Supplier Legacy Award from Premier Inc. ( www.premierinc.com ), a leading health care improvement company.
  • Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to cost optimizations, according to Premier.
  • Thats why its particularly gratifying to receive this recognition from Premier, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Legacy Award winners have a tenure of more than three years as a Premier contracted supplier.

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Friday, June 11, 2021 - 12:30pm

Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.

Key Points: 
  • Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.
  • Under a Distribution Agreement entered into in June 2018, Fresenius Medical Care obtained the exclusive global rights to commercialize Humacytes HAVs in the applications of vascular access for hemodialysis and peripheral arterial disease.
  • We are pleased to expand our partnership with Fresenius Medical Care, the worlds leading care provider for patients undergoing kidney replacement therapy, said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Fresenius Medical Care has a network of more than 4,000 dialysis centers worldwide, and cares for over 300,000 patients with end-stage renal failure.

OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

Monday, May 24, 2021 - 12:30pm

MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).

Key Points: 
  • MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
  • RAYALDEE is an extended release formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3.
  • RAYALDEE is approved to treat SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in the U.S. and 11 European countries.
  • Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care) is part of the Vifor Pharma Group (VPG), a global pharmaceutical company.